Versican and its associated molecules: potential diagnostic markers for multiple myeloma

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Multiple myeloma (MM) is a B-cell malignancy involving plasma cell proliferation in bone marrow.
• Versican (VCAN), an extracellular matrix protein, is implicated in various cancer processes.
• Identifying diagnostic markers for MM is crucial for disease management.

Purpose of the Study:

• To investigate the expression of Versican (VCAN) and associated molecules in multiple myeloma (MM).
• To evaluate the diagnostic utility of VCAN and its related molecules as potential biomarkers for MM.
• To determine the association of VCAN and its associated molecules with disease severity in MM patients.

Main Methods:

• Expression analysis of VCAN, β-catenin, β1 integrin, and FAK in 60 subjects.
• Analysis of circulatory and molecular levels in bone marrow (BM) and blood using ELISA, Q-PCR, and western blotting.
• Receiver Operating Characteristic (ROC) curve analysis for diagnostic evaluation.

Main Results:

• Significantly elevated circulatory levels of VCAN, β-catenin, and FAK were observed in MM patients across different stages.
• Intracellular levels of β-catenin and FAK, as well as mRNA levels of all investigated molecules, were significantly higher in patients.
• VCAN demonstrated high sensitivity and specificity for MM diagnosis in serum, confirmed by ROC analysis.

Conclusions:

• The significant elevation of VCAN and associated molecules suggests their involvement in the pathogenesis of MM.
• VCAN's optimal sensitivity and specificity highlight its potential as a valuable biomarker for detecting active multiple myeloma.
• These findings underscore the potential of VCAN as a diagnostic tool for MM.